$0.56 EPS Expected for NuVasive, Inc. (NUVA)

January 20, 2018 - By Peter Erickson

 $0.56 EPS Expected for NuVasive, Inc. (NUVA)
Investors sentiment decreased to 0.95 in Q3 2017. Its down 0.28, from 1.23 in 2017Q2. It worsened, as 67 investors sold NuVasive, Inc. shares while 69 reduced holdings. 47 funds opened positions while 82 raised stakes. 53.88 million shares or 3.45% less from 55.81 million shares in 2017Q2 were reported.
Millennium Mgmt Ltd Liability Com has 40,421 shares for 0% of their portfolio. Commercial Bank Of Montreal Can accumulated 8,669 shares. Primecap Mngmt Ca has 0.04% invested in NuVasive, Inc. (NASDAQ:NUVA) for 835,200 shares. Bnp Paribas Arbitrage Sa stated it has 23,549 shares or 0% of all its holdings. The Pennsylvania-based Cim Mangement has invested 0.11% in NuVasive, Inc. (NASDAQ:NUVA). Sector Gamma As reported 183,000 shares. Mason Street reported 25,216 shares. Sectoral Asset accumulated 0.95% or 132,290 shares. Paloma Prns Mgmt Com accumulated 21,598 shares. The Pennsylvania-based Vanguard Grp Incorporated Inc has invested 0.01% in NuVasive, Inc. (NASDAQ:NUVA). Goldman Sachs Grp holds 0.02% in NuVasive, Inc. (NASDAQ:NUVA) or 1.81M shares. Ameriprise Fincl invested in 144,721 shares. Campbell Newman Asset Mngmt holds 0.04% in NuVasive, Inc. (NASDAQ:NUVA) or 4,174 shares. Rhumbline Advisers owns 122,785 shares. Icon Advisers has 6,500 shares.

Since August 17, 2017, it had 0 insider purchases, and 1 insider sale for $256,621 activity.

Analysts expect NuVasive, Inc. (NASDAQ:NUVA) to report $0.56 EPS on February, 8.They anticipate $0.03 EPS change or 5.66 % from last quarter’s $0.53 EPS. NUVA’s profit would be $28.54 million giving it 23.25 P/E if the $0.56 EPS is correct. After having $0.52 EPS previously, NuVasive, Inc.’s analysts see 7.69 % EPS growth. The stock increased 2.54% or $1.29 during the last trading session, reaching $52.08. About 1.39M shares traded or 56.74% up from the average. NuVasive, Inc. (NASDAQ:NUVA) has risen 33.31% since January 20, 2017 and is uptrending. It has outperformed by 16.61% the S&P500.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

Among 22 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. Nuvasive Inc. had 64 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, July 28, the company rating was maintained by Cowen & Co. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, October 25. The stock has “Buy” rating by Canaccord Genuity on Tuesday, September 19. The company was maintained on Tuesday, October 3 by Jefferies. The stock of NuVasive, Inc. (NASDAQ:NUVA) earned “Buy” rating by Cowen & Co on Monday, October 16. The stock of NuVasive, Inc. (NASDAQ:NUVA) earned “Buy” rating by RBC Capital Markets on Sunday, August 20. The firm has “Outperform” rating given on Thursday, July 30 by Northland Capital. The stock has “Buy” rating by Jefferies on Thursday, June 29. Canaccord Genuity maintained NuVasive, Inc. (NASDAQ:NUVA) on Thursday, January 4 with “Buy” rating. JP Morgan upgraded NuVasive, Inc. (NASDAQ:NUVA) rating on Wednesday, July 13. JP Morgan has “Overweight” rating and $74 target.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. The company has market cap of $2.65 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. It has a 44.74 P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

More recent NuVasive, Inc. (NASDAQ:NUVA) news were published by: Prnewswire.com which released: “NuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And …” on January 08, 2018. Also Seekingalpha.com published the news titled: “A Sluggish Spine Market Keeping The Pressure On NuVasive” on January 10, 2018. Prnewswire.com‘s news article titled: “NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF …” with publication date: January 04, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: